Last reviewed · How we verify
Oxaliplatin during radiotherapy
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, and when combined with radiotherapy, enhances radiation-induced cell death through synergistic DNA damage.
Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, and when combined with radiotherapy, enhances radiation-induced cell death through synergistic DNA damage. Used for Locally advanced colorectal cancer (in combination with radiotherapy), Rectal cancer (neoadjuvant chemoradiotherapy).
At a glance
| Generic name | Oxaliplatin during radiotherapy |
|---|---|
| Sponsor | Universitätsmedizin Mannheim |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Oxaliplatin binds to DNA and forms interstrand and intrastrand crosslinks, preventing DNA replication and transcription. When administered concurrently with radiotherapy, it acts as a radiosensitizer, potentiating the cytotoxic effects of ionizing radiation by inhibiting DNA repair mechanisms and increasing apoptosis in cancer cells.
Approved indications
- Locally advanced colorectal cancer (in combination with radiotherapy)
- Rectal cancer (neoadjuvant chemoradiotherapy)
Common side effects
- Peripheral neuropathy
- Nausea and vomiting
- Diarrhea
- Myelosuppression
- Fatigue
- Mucositis
Key clinical trials
- Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (PHASE2)
- Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer (PHASE1)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） (PHASE2)
- Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer (PHASE2)
- Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaliplatin during radiotherapy CI brief — competitive landscape report
- Oxaliplatin during radiotherapy updates RSS · CI watch RSS
- Universitätsmedizin Mannheim portfolio CI